NASDAQ:XGN - Exagen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.50
  • Forecasted Upside: 50.44 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$16.95
▲ +1.97 (13.15%)
1 month | 3 months | 12 months
Get New Exagen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$25.50
▲ +50.44% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Exagen in the last 3 months. The average price target is $25.50, with a high forecast of $33.00 and a low forecast of $18.00. The average price target represents a 50.44% upside from the last price of $16.95.

Buy

The current consensus among 5 polled investment analysts is to buy stock in Exagen.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2021Canaccord GenuityInitiated CoverageBuy$25.00Medium
i
3/17/2021CowenBoost Price TargetOutperform$21.00 ➝ $26.00Medium
i
3/2/2021KeyCorpBoost Price TargetOverweight$32.00 ➝ $33.00High
i
11/11/2020William BlairReiterated RatingOutperformMedium
i
Rating by B. Weinstein at William Blair
11/10/2020KeyCorpInitiated CoverageOverweight$32.00Low
i
11/9/2020KeyCorpInitiated CoverageOverweightLow
i
10/8/2020BTIG ResearchInitiated CoverageBuy$18.00High
i
6/1/2020Cantor FitzgeraldInitiated CoverageOverweight$19.00 ➝ $20.00Low
i
Rating by Craig Bijou at Cantor Fitzgerald
5/21/2020Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by K. Mikson at Cantor Fitzgerald
3/26/2020Cantor FitzgeraldLower Price TargetOverweight$25.00 ➝ $19.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
3/2/2020Cantor FitzgeraldReiterated RatingBuy$25.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
10/14/2019Cantor FitzgeraldInitiated CoverageOverweight$18.00Low
i
Rating by C. Bijou at Cantor Fitzgerald
10/14/2019William BlairInitiated CoverageOutperformLow
i
Rating by B. Weinstein at William Blair
10/14/2019CowenInitiated CoverageOutperform$17.00Low
i
(Data available from 6/14/2016 forward)
Exagen logo
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Read More

Today's Range

Now: $16.95
$14.70
$17.16

50 Day Range

MA: $15.12
$12.40
$17.68

52 Week Range

Now: $16.95
$10.29
$24.67

Volume

80,771 shs

Average Volume

59,368 shs

Market Capitalization

$286.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Exagen?

The following sell-side analysts have issued research reports on Exagen in the last year: BTIG Research, Canaccord Genuity, Cowen Inc, KeyCorp, TheStreet, William Blair, and Zacks Investment Research.
View the latest analyst ratings for XGN.

What is the current price target for Exagen?

4 Wall Street analysts have set twelve-month price targets for Exagen in the last year. Their average twelve-month price target is $25.50, suggesting a possible upside of 70.2%. KeyCorp has the highest price target set, predicting XGN will reach $33.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $18.00 for Exagen in the next year.
View the latest price targets for XGN.

What is the current consensus analyst rating for Exagen?

Exagen currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XGN will outperform the market and that investors should add to their positions of Exagen.
View the latest ratings for XGN.

What other companies compete with Exagen?

How do I contact Exagen's investor relations team?

Exagen's physical mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The company's listed phone number is 760 560 1501 and its investor relations email address is [email protected] The official website for Exagen is www.exagen.com.